Filing Details
- Accession Number:
- 0001562180-20-006560
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-04 20:31:03
- Reporting Period:
- 2020-11-02
- Accepted Time:
- 2020-11-04 20:31:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1373097 | Jr A William Jones | C/O Biohaven Pharmaceuticals 215 Church Street New Haven CT 06510 | Cco-Migraine & Common Disease | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2020-11-02 | 30,000 | $50.72 | 31,755 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2020-11-02 | 24,690 | $76.02 | 7,065 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-11-02 | 4,010 | $77.01 | 3,055 | No | 4 | S | Direct | |
| Common Shares | Disposition | 2020-11-02 | 1,300 | $77.70 | 1,755 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Employee Stock Option (Right to Buy) | Disposition | 2020-11-02 | 30,000 | $0.00 | 30,000 | $50.72 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 50,000 | 2029-03-31 | No | 4 | M | Direct |
Footnotes
- These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.53 - $76.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.54 - $77.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.55 - $77.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- The shares underlying this option vest in three equal installments on April 1, 2019, April 1, 2020 and April 1, 2021, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Billionaire Hedge Funds
